Administration of a dietary supplement (N-oleyl-phosphatidylethanolamine and epigallocatechin-3-gallate formula) enhances compliance with diet in healthy overweight subjects: A randomized controlled trial

British Journal of Nutrition

Volumn 101, Issue 3, 2009, Pages 457-464

  Rondanelli, Mariangela ^a,b   Opizzi, Annalisa ^a,b   Solerte, Sebastiano Bruno ^b   Trotti, Rosita ^c   Klersy, Catherine ^d   Cazzola, Roberta ^e  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Appetite; Dietary adherence; Epigallocatechin 3 gallate; Insulin resistance; N oleyl phosphatidylethanolamine

Indexed keywords

EPIGALLOCATECHIN GALLATE; N OLEYLPHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLETHANOLAMINE; PLACEBO; UNCLASSIFIED DRUG; ANOREXIGENIC AGENT; BIOLOGICAL MARKER; CATECHIN; DRUG DERIVATIVE; INSULIN; N OLEYL PHOSPHATIDYLETHANOLAMINE; N-OLEYL-PHOSPHATIDYLETHANOLAMINE;

ARTICLE; BINGE EATING DISORDER; BODY COMPOSITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DECREASED APPETITE; DEPRESSION; DIET RESTRICTION; DIET SUPPLEMENTATION; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPIGASTRIC FULLNESS; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION; ADOLESCENT; ADULT; BLOOD; CONTROLLED STUDY; EATING; GLUCOSE BLOOD LEVEL; LOW CALORY DIET; MIDDLE AGED; NONPARAMETRIC TEST; SATIETY;

ADOLESCENT; ADULT; APPETITE DEPRESSANTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY COMPOSITION; CATECHIN; DEPRESSION; DIET, REDUCING; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; EATING; FEMALE; HUMANS; INSULIN; MALE; MIDDLE AGED; OVERWEIGHT; PATIENT COMPLIANCE; PHOSPHATIDYLETHANOLAMINES; SATIATION; STATISTICS, NONPARAMETRIC; WEIGHT LOSS;

EID: 66849109228     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114508024008     Document Type: Article

References (42)

1. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, Rimm E & Colditz GA (2001) Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 161 1581-1586.
2. Pittler MH & Ernst E (2005) Complementary therapies for reducing body weight: A systematic review. Int J Obes 29, 1030-1038.
3. Arterburn D & Noël PH (2001) Extracts from 'Clinical Evidence'. Obesity. Br Med J 322, 1406-1409.
4. Melin I, Reynisdottir S, Berglund L, Zamfir M & Karlstrom B (2006) Conservative treatment of obesity in an academic obesity unit. Long-term outcome and drop-out. Eat Weight Disord 11, 22-30.
5. Teixeira PJ, Going SB, Houtkooper LB, Cussler EC, Metcalfe LL, Blew RM, Sardinha LB & Lohman TG (2004) Pretreatment predictors of attrition and successful weight management in women. Int J Obes Relat Metab Disord 28, 1124-1133.
6. Teixeira PJ, Palmeira AL, Branco TL, Martins SS, Minderico CS, Barata JT, Silva AM & Sardinha LB (2004) Who will lose weight? A reexamination of predictors of weight loss in women. Int J Behav Nutr Phys Act 1, 12.
7. Higdon JV & Frei B (2003) Tea catechins and polyphenols: Health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 43, 89-143.
8. Mitscher LA, Jung M, Shankel D, Dou JH, Steele L & Pillai SP (1997) Chemoprotection: A review of the potential therapeutic antioxidant properties of green tea (Camellia sinensis) and certain of its constituents. Med Res Rev 17, 327-365.
9. Kao YH, Hiipakka RA & Liao S (2000) Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. Endocrinology 141, 980-987.
10. Dulloo AG, Duret C, Rohrer D, Girardier L, Mensi N, Fathi M, Chantre P & Vandermander J (1999) Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr 70, 1040-1045.
11. Williamson G & Manach C (2005) Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr 81, S243-S255.
12. Chen L, Lee MJ, Li H & Yang CS (1997) Absorption, distribution, elimination of tea polyphenols in rats. Drug Metab Dispos 25 1045-1050.
13. Schmid HH, Schmid PC & Natarajan V (1990) N-acylated glycerophospholipids and their derivatives. Prog Lipid Res 29 1-43.
14. Chapman KD & Moore TS Jr (1993) N-acylphosphatidylethanolamine synthesis in plants: Occurrence, molecular composition, and phospholipid origin. Arch Biochem Biophys 301, 21-33.
15. Di Tomaso E, Beltramo M & Piomelli D (1996) Brain cannabinoids in chocolate. Nature 382, 677-678.
16. Williams CM & Kirkham TC (1999) Anandamide induces overeating: Mediation by central cannabinoid (CB1) receptors. Psychopharmacology 143 315-317.
17. Fu J, Gaetani S, Oveisi F, et al. (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425, 90-93.
18. Overton HA, Babbs AJ, Doel SM, et al. (2006) Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 3, 167-175.
19. Broccali G, Berti M, Pistolesi E & Cestaro B (2005) N oleoylphosphatidylethanolamine reduces food intake and body weight of dietary obese rats ameliorating their antioxidant status. Gazz Med Ital Arch Sci Med 164, 101-107.
20. American Psychiatric Association (1994) Mood disorders. In Diagnostic and Statistical Manual of Mental Disorders, 4th ed., pp. 317-345 [American Psychiatric Association, editor]. Washington, DC: American Psychiatric Association.
21. World Health Organization (1985) Energy and Protein Requirements, Joint FAO/WHO/UNU Expert Consultation. WHO Technical Report Series no. 724. Geneva: WHO.
22. Frisancho AR (1984) New standards of weight and body composition by frame size and height for assessment of nutritional status of adults and the elderly. Am J Clin Nutr 40, 808-819.
23. Blackburn G (1995) Effect of degree of weight loss on health benefits. Obes Res 3, S211-S216.
24. Goldstein DJ (1992) Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 16, 397-415.
25. Kushner RF (1992) Bioelectrical impedance analysis: A review of principles and applications. J Am Coll Nutr 11, 199-209.
26. Friedewald WT, Levy RI & Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18, 499-502.
27. Haffner SM, Kennedy E, Gonzalez C, Stern MP & Miettinen H (1996) A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 19, 1138-1141.
28. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G & Quon MJ (2000) Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85, 2402-2410.
29. Haber GB, Heaton KW, Murphy D & Burroughs LF (1977) Depletion and disruption of dietary fibre. Effects on satiety, plasma-glucose and serum insulin. Lancet ii, 679-682.
30. Gormally J, Black S, Daston S & Rardin D (1982) The assessment of binge eating severity among obese persons. Addict Behav 7, 47-55.
31. Steer RA, Ball R, Ranieri WF & Beck AT (1999) Dimensions of the Beck Depression Inventory-II in clinically depressed outpatients. J Clin Psychol 55, 117-128.
32. Wang X, Miyares RL & Ahern GP (2005) Oleoylethanolamide excites vagal sensory neurons, induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1. J Physiol 564, 541-547.
33. Khaodhiar L, McCowen KC & Blackburn GL (1999) Obesity and its comorbid conditions. Clin Cornerstone 2, 17-31.
34. Lamberg L (2000) Psychiatric help may shrink some waistlines. JAMA 284, 291-293.
35. Fitzgibbon ML, Stolley MR & Kirschenbaum DS (1993) Obese people who seek treatment have different characteristics than those who do not seek treatment. Health Psychol 12, 342-345.
36. Wadden TA, Womble LG, Stunkard AJ & Anderson DA (2002) Psychosocial consequences of obesity and weight loss. In Handbook of Obesity Treatment, pp. 144-169 [TA Wadden and AJ Stunkard, editors]. New York: Guilford Press.
37. MacLachlan M, Connacher AA & Jung RT (1991) Psychological aspects of dietary weight loss and medication with the a typical beta agonist BRL 26830A in obese subjects. Int J Obes 15, 27-35.
38. Adachi N, Tomonaga S, Tachibana T, Denbow DM & Furuse M (2006) Epigallocatechin gallate attenuates acute stress responses through GABAergic system in the brain. Eur J Pharmacol 531, 171-175.
39. Vignes M, Maurice T, Lante' F, Nedjar M, Thethi K, Guiramand J & Récasens M (2006) Anxiolytic properties of green tea polyphenol (-)epigallocatechin gallate (EGCG). Brain Res 1110, 102-115.
40. Hoffman AF, Oz M, Caulder T & Lupica CR (2003) Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure. J Neurosci 23, 4815-4820.
41. Sari R, Balci MK, Altunbas H & Karayalcin U (2003) The effect of body weight and weight loss on thyroid volume and function in obese women. Clin Endocrinol 59, 258-262.
42. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA 295, 761-775.